Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (hepatocytes) | 0.10 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 15 Parkinson's papers of 7,044 | 0.64 |
| pathways Reactome | 5 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 9420
Sealed predictions
- CYP2C19 in dopamine neurons, braak+0.02 (p 0.964) → +0.17 (p 0.654)receipt 9427
Swarm cases
receipt 9427: CYP2C19 in dopamine neurons, braak
- power
- full sample +0.20 (p 0.418, n 18), 95% CI -0.29 to +0.61. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.28 (p 0.265, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.19 (p 0.450, n 18). could be the mix.
- skeptic
- leave-one-out range +0.13 to +0.39, sign flips 0; without severely affected donors +0.20 (p 0.418, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CYP2C19 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts